The company will use the proceeds to test its gene therapy XC001 in two Phase II studies involving patients with cardiovascular disease.

Ferring Pharma’s Adstiladrin is a non-replicating (cannot multiply in human cells) adenoviral vector-based gene therapy. Its safety and efficacy was evaluated in a multi-centre clinical study of ...

for development of adenovirus-based gene therapies. That same year Novartis also formed a strategic alliance with GlaxoSmithKline and the Telethon Institute of Gene Therapy (TIGET) to pursue ...

The researcher has given an overview on the regulatory network of extracellular circRNAs in cancer and their impact on cancer drug resistance. In order to propagate malignancy, circRNAs shuttle ...

A study published in Human Gene Therapy has involved the generation of a human monoclonal antibody (mAb) directed against ...

A new study published in the peer-reviewed journal Human Gene Therapy involved the generation of a human monoclonal antibody ...

Gene therapy firm Capsida Biotherapeutics is advancing the first of its AbbVie-partnered neurodegenerative disease therapies ...

In a finding with implications for one of the most promising cutting-edge medical treatments, researchers evaluated several ...

The science has proven that gene therapies are effective treatments, and they have given hope to patients and their families ...

We show here that inhibition of NF-κB through the adenoviral delivery of a modified ... inhibition of NF-κB as a new approach to adjuvant therapy in cancer treatment. Figure 1: TNFα induces ...

University of California San Diego Health now offers a new gene therapy for hemophilia B, a bleeding disorder that prevents ...